NUVL Stock Rallies 14% on Breakthrough ALK Inhibitor Trial Success

Nuvalent's lead candidate neladalkib (NVL-655) has delivered compelling clinical evidence that's reshaping investor sentiment around the biotech firm. The pivotal ALKOVE-1 trial demonstrated robust efficacy in a challenging patient population—those with ALK-positive non-small cell lung cancer (NSCLC) who had already received prior tyrosine kinase inhibitor (TKI) therapy.

The trial results reveal meaningful advances in response rates and treatment durability, establishing neladalkib as a potential best-in-class option within the ALK inhibitor landscape for heavily pretreated disease. This outcome addresses a significant clinical need, as patients with acquired resistance to previous TKI regimens have limited therapeutic options.

Market enthusiasm materialized immediately. Nuvalent (NUVL) shares surged 14.24% to $110.24 per share, gaining $13.74 in a single session driven by robust trading activity. The stock movement reflects investor confidence in the drug's commercial potential and Nuvalent's positioning within the competitive ALK-focused treatment space.

The company's 52-week trading range spans from $55.30 to $110.24, with the recent rally pushing the stock toward its upper valuation boundary. Strong clinical validation typically catalyzes institutional interest in biotech plays, particularly when late-stage data de-risks regulatory pathways and hints at market expansion opportunities.

**Note:** The views expressed are for informational purposes and do not represent those of Nasdaq, Inc.